Company: DHR
Filing Date: 2025-02-20
Form Type: 10-K
Source: 0000313616-25-000043
Chunk: 219

Company: DANAHER CORP /DE/
Filing Date: 2025-02-20
Form: 10-K
Item: Item 5
Chunk 219
---
9,577 $— $23,890 Less:Depreciation(162)(129)(379)(5)(675)Amortization of intangible assets(864)(429)(198)— (1,491)Impairments(b)(54)— (23)— (77)Other segment expenses(c)(4,183)(5,374)(6,571)(317)(16,445)Operating profit$1,909 $1,209 $2,406 $(322)$5,202 Year Ended December 31, 2022Sales (GAAP)$8,758 $7,036 $10,849 $— $26,643 Less:Depreciation(190)(112)(387)(9)(698)Amortization of intangible assets(812)(419)(203)— (1,434)Other segment expenses(c)(4,748)(5,091)(6,823)(313)(16,975)Operating profit$3,008 $1,414 $3,436 $(322)$7,536 (a) Other consists of unallocated corporate costs and other costs not considered part of management’s evaluation of reportable segment operating performance.(b) For information on the impairments, refer to Note 10. (c) Other segment expenses for each reportable segment include cost of sales, selling general and administrative expenses, research and development (“R&D”) expenses, excluding depreciation, amortization of intangible assets and impairments.  Included within these categories of expenses are overhead expenses, stock compensation expense, restructuring charges and allocated corporate expenses. 

72

The following table presents additional detailed segment data for the years ended December 31 ($ in millions):202420232022Identifiable assets:Biotechnology$34,605 $37,421 $37,536 Life Sciences23,211 23,730 17,572 Diagnostics14,204 14,552 14,722 Other5,522 8,785 9,739 Discontinued operations— — 4,781 Total$77,542 $84,488 $84,350 Capital expenditures, gross:Biotechnology$447 $417 $405 Life Sciences391 320 325 Diagnostics550 546 382 Other4 100 6 Total$1,392 $1,383 $1,118 Operations in Geographical Areas: